TheEdgeResearch
Home / Stocks / ZLAB

Zai Lab Limited (ZLAB)

NASDAQ Healthcare Biotechnology
$21.03 ▼ -4.06%
Market Cap
$2.37B
Sector
Healthcare
Industry
Biotechnology
Beta
0.83
52-Wk Range
15.96-29.02
CEO
Ying Du
Country
CN
Currency
USD

Zai Lab Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $21.03, down 4.06% on the session, giving a market capitalisation of $2.37B. On trailing twelve-month figures it carries a trailing P/E of -11.56, a net margin of -44.9%. Its beta of 0.83 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-11.56
Price / Sales
5.91
Price / Book
4.17
EV / EBITDA
-10.72
Gross margin
54.7%
Operating margin
-63.0%
Net margin
-44.9%
Return on equity
—
Debt / equity
0.47
Current ratio
2.04
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
1,784
IPO date
2017-09-20
Headquarters
Shanghai, SH, CN
About Zai Lab Limited

Zai Lab Limited, established in 2013 and based in Shanghai, China, is a biopharmaceutical company dedicated to developing and bringing to market innovative medical treatments. Its core focus spans oncology, autoimmune diseases, infectious diseases, and neurological conditions, primarily serving patients in Mainland China and Hong Kong. The company's portfolio of commercialized products includes Zejula, an oral, once-daily poly polymerase 1/2 inhibitor; Optune, a non-invasive device employing tumor treating fields; NUZYRA for addressing acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Zai Lab also maintains a robust pipeline of investigational therapies. This pipeline features numerous oncology assets such as Odronextamab for various lymphomas, Repotrectinib—a tyrosine kinase inhibitor targeting ROS1 and TRK fusions, Margetuximab for breast and gastroesophageal cancers, Adagrasib for KRAS-G12C-mutated solid tumors, and Bemarituzumab for gastric and gastroesophageal junction cancers. Other notable pipeline candidates include CLN-081 for specific non-small cell lung cancers, multi-targeted kinase inhibitors like Elzovantinib, several monoclonal antibodies (e.g., Tebotelimab, Retifanlimab, ZL-1201), and immune modulators such as Efgartigimod for reducing disease-causing IgG antibodies and ZL-1102 targeting IL-17A. Additionally, the company is advancing therapies like KarXT for psychiatric and neurological disorders, novel EGFR inhibitors (ZL-2313, ZL-2314), a CDC7 kinase inhibitor (ZL-2309), and Sulbactam/durlobactam for serious Acinetobacter infections, showcasing its commitment to a broad range of therapeutic innovations.

Comparable companies

Zai Lab Limited is most often compared with the following Healthcare names:

AAPGANLHCM
More research on ZLAB
ZLAB technical analysis ZLAB TheEdge Score Compare against peers
Open full interactive analysis & DCF →